Researchers discover treatable cause of severe anemia associated with a cancer therapy

Researchers at the Mount Sinai Tisch Cancer Center have identified that severe anemia in patients taking PARP inhibitors is often caused by folate deficiency rather than bone marrow suppression. This discovery suggests that routine screening and folic acid supplementation could prevent complications and treatment interruptions for cancer patients.